Neonatal opioid withdrawal syndrome (NOWS) has risen in prevalence from 1.2 per 1000
births in 2000 to 5.8 per 1000 births in 2012. Symptoms in neonates may include high …

Objectives: The prevalence of opioid use disorder (OUD) during pregnancy is increasing.
Practical recommendations will help providers treat pregnant women with OUD and reduce …

Many mothers are inappropriately advised to discontinue breastfeeding or avoid taking
essential medications because of fears of adverse effects on their infants. This cautious …

Background Methadone, a full mu-opioid agonist, is the recommended treatment for opioid
dependence during pregnancy. However, prenatal exposure to methadone is associated …

A central goal of The Academy of Breastfeeding Medicine is the development of clinical
protocols for managing common medical problems that may impact breastfeeding success …

Background: The Academy of Breastfeeding Medicine (ABM) revised the 2015 version of the
substance use disorder (SUD) clinical protocol to review the evidence and provide updated …

Buprenorphine is a semi-synthetic opioid derived from thebaine, a naturally occurring
alkaloid of the opium poppy, Papaver somniferum. The pharmacology of buprenorphine is …

Objective. This was a prospective longitudinal multisite study of the effects of prenatal
cocaine and/or opiate exposure on neurodevelopmental outcome in term and preterm …

In the past three decades, there has been increased recognition of the role of gender in
influencing the course of substance use and treatment utilization. Concurrently, a substantial …

Objective. This was a prospective study of the effects of maternal smoking during pregnancy
on newborn neurobehavior, including dose-response relationships using self-report and a …